Program
itepekimab
Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.
Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.
Drug pageItepekimab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 123 open or running | phase 3since Dec 30, 2020 | Dec 15, 2017 | Feb 17, 2027phase 3 · NCT07424144 |
| Regeneron Pharmaceuticalsits history only | 50 open or running | phase 2since Nov 7, 2018 | Oct 25, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 15, 2017First study: phase 2 study in AsthmaFirst studyNCT03387852 · 296 enrolled · United States, Argentina, Chile and more
- May 17, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03546907 · 343 enrolled · United States, Argentina, Australia and more
- Dec 9, 2019Named itepekimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, REGN3500, SAR440340
- Dec 30, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04701983 · 1,127 enrolled · United States, Argentina, Bulgaria and more
- Feb 8, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04751487 · 1,234 enrolled · United States, Argentina, Brazil and more
- Apr 6, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05326412 · 49 enrolled · United States, Belgium, Brazil and more
- Jan 5, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06208306 · 669 enrolled · United States, Argentina, Brazil and more
- Feb 20, 2024Phase 2 study in BronchiectasisNCT06280391 · 314 enrolled · United States, Argentina, Brazil and more
- Nov 12, 2024Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsNCT06691113 · 66 enrolled · United States, Argentina, Belgium and more
- Feb 14, 20252 phase 3 studies in Chronic Rhinosinusitis With Nasal PolypsNCT06834360, NCT06834347
- Feb 13, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07424144 · 59 enrolled · United States, Argentina, Australia and more
- Mar 16, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07484230
Ahead
- Feb 17, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07424144
TargetBeta
“Interleukin-33 inhibitor”ChEMBL 37, by rule
Other programs on IL33
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| GSK3862995B | GlaxoSmithKline | phase 2 | 5 |
| ompekimig | Pfizer | phase 2 | 3 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 12 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07484230Chronic Rhinosinusitis With Nasal Polyps | 3 | Withdrawn | Oct 20, 2027 | 0 |
| NCT07424144Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 17, 2027 | 59 |
| NCT06834360Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 24, 2026 | 216 |
| NCT06834347Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Austria and more | 3 | Active, not recruiting | Sep 23, 2026 | 231 |
| NCT06691113Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Belgium and more | 2 | Completed | Mar 31, 2026 | 66 |
| NCT06280391Bronchiectasis · United States, Argentina, Brazil and more | 2 | Completed | Sep 16, 2025 | 314 |
| NCT06208306Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more | 3 | Completed | Sep 10, 2026 | 669 |
| NCT05326412Pulmonary Disease, Chronic Obstructive · United States, Belgium, Brazil and more | 2 | Completed | Mar 5, 2025 | 49 |
| NCT04751487Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more | 3 | Completed | Apr 21, 2025 | 1,234 |
| NCT04701983Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | Apr 11, 2025 | 1,127 |
| NCT03546907Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 2 | Completed | Oct 3, 2019 | 343 |
| NCT03387852Asthma · United States, Argentina, Chile and more | 2 | Completed | Mar 21, 2019 | 296 |
How it is read
Names in the registry
- “Itepekimab (SAR440340)”, 7 entries
- “REGN3500”, 5 entries
- “Itepekimab SAR440340”, 3 entries
- “SAR440340”, 2 entries
Conditions, from the studies’ own filings
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 5 studies
- Asthma, 3 studies
- Dermatitis, Atopic, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.